? Flow Cytometry and Cell Sorting Facility The Flow Cytometry and Cell Sorting Facility at the Abramson Cancer Center (ACC) has been continuously funded by the NCI Cancer Center Support Grant since 1981. The Facility is recognized as a worldwide leader in cytometry and cytomics and is one of the largest and most comprehensive academic flow cytometry Shared Resources in North America. A full range of cytomic services is offered including analytical cytometry of up to 30 parameters, detection and analysis of extracellular vesicles, basic and ultra-rare cell sorting, single cell multiomic analysis, computational cytomic data analysis, permanent data archive, expert consultation, and a comprehensive education program. Jonni Moore, PhD, Professor of Pathology and Laboratory Medicine with a doctorate in immunology, has directed the Facility since 1990. She is the 2020-2022 President of the International Society for the Advancement of Cytometry (ISAC), a noted expert in deep phenotyping and extracellular vesicle cytometry, and a highly respected expert in Shared Resource operation. The leadership team also includes Thomas Williams, BS, SCYM(ASCP)CM, the new Technical Director of Operations and Client Services, with more than 30 years of Shared Resource leadership. Derek Jones, PhD, SCYM(ASCP)CM, the new Director for Research and Development, is an immunology PhD recently selected as an ISAC Shared Resource Emerging Leader. This team is supported by eight other full time-equivalent staff with an average of 15 years' experience. With cutting-edge cytomic technology and instrumentation, and extensive expertise, ACC members have access to complete experimental design and technical support, data analysis and interpretation. During the current period, the Facility continued to experience significant growth, reflecting the recent expanded interest in cell-based analysis in cancer research. ACC members accounted for 113 of 255 researchers (44%) who used the Facility during this reporting period (July 1, 2018 through June 30, 2019). The Facility supported multiple high impact studies, including the elucidation of immunological and clinical response to PD-1 blockade leading to novel mechanistic insights and provoking new clinical trials (Huang et al., Nat Med, 2019; Huang et al., Nature, 2017). The success of the Facility can be attributed to several factors: hiring and retaining highly qualified staff (by creating a new career track for Shared Resource laboratory staff); constant evaluation and subsequent purchase of the most cutting-edge instrumentation; the use of satellite facilities, with 24/7 access, purposefully located near major user groups; implementation of a highly effective training program; major operational IT support (on-line scheduling, central archiving of data, site-licensing software to investigators to perform data analysis in their laboratories). This results in a highly cost-effective operation offering ACC investigators access to world class expertise in cytomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088761
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5

Showing the most recent 10 out of 1047 publications